Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

10-03-2015 | Uterine cancer | Article

Optimal follow-up of endometrial cancer patients

Journal: memo - Magazine of European Medical Oncology

Authors: Eduard Vrdoljak, MD, PhD, Tihana Boraska Jelavić, MD, PhD, Branka Petrić Miše, MD, PhD

Publisher: Springer Vienna

Login to get access

Abstract

Gynecological malignancies account round 10 % of all female cancers, with the uterine cancer being the most predominant one. Surveillance programs of all gynecologic cancers are primarily based on recurrence rates, timing of recurrence, salvage options and chances for cure of patient with recurrence. Since there is no prospective, high evidence data about optimal surveillance program after primary treatment of patients with endometrial cancer recommendations are based on review of retrospective data sets. From all the diagnostic tools available, history taking and clinical examination, including comprehensive gynecological examination, still contribute to the greatest number of recurrence detection. Radiologic tests are usually employed when a suspicion of recurrence is raised. Follow-up plan should be tailored according to the estimated risk of relapse for individual patient.
Literature
1.
Creutzberg CL, van Putten WLJ, Koper PCM, et al. for the PORTEC Study Group. Surgery and radiotherapy versus surgery alone for patients with stage –1 endometrial carcinoma: multicentre randomised trial. Lancet. 2000;355:1404–11.CrossRefPubMed
2.
Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:744–51.CrossRefPubMed
3.
Nout RA, Smit VTHBM, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010;375:816–23.CrossRefPubMed
4.
Ben Arie A, Lavie O, Gdalevich M, et al. Temporal pattern of recurrence of stage I endometrial cancer in relation to histological risk factors. Eur J Surg Oncol. 2012;38(2):166–9.CrossRefPubMed
5.
Simpkins F, Papadia A, Kunos C, et al. Patterns of recurrence in stage I endometrioid endometrial adenocarcinoma with lymphovascular invasion. Int J Gynecol Cancer. 2013;23(1):98–104.CrossRefPubMed
6.
Fung-Kee-Fung M, Dodge J, Elit L, et al. Follow-up after primary therapy for endometrial cancer: a systematic review. Gynecol Oncol. 2006;101:520–9.CrossRefPubMed
7.
Milgrom SA, Kollmeier MA, Abu-Rustum NR, O’Cearbhaill RE, Barakat RR, Alektiar KM. Quantifying the risk of recurrence and death in stage III (FIGO 2009) endometrial cancer. Gynecol Oncol 2014;134:297–301. http://​dx.​doi.​org/​10.​1016/​j.​ygyno.​ Accesssed: 13 May 2014.CrossRefPubMed
8.
Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10–7.CrossRefPubMed
9.
Ayeni TA, Bakkum-Gamez JN, Mariani A, et al. Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas. Gynecol Oncol. 2013;129:478–85.CrossRefPubMed
10.
Sartori E, Pasinetti B, Chiudinelli F, et al. Surveillance procedures for patients treated for endometrial cancer: a review of the literature. In J Gynecol Cancer. 2010;20(6):985–92.CrossRef
11.
Sartori E, Lafare B, Gadducci a, et al. Factors influencing survival in endometrial cancer relapsing patients: a Cooperation Task Force (CTF) study. Int J Gynecol Cancer. 2003;13:458–65.CrossRefPubMed
12.
Moschiano EJ, Barbuto DA, Walsh C, et al. Risk factors for recurrence and prognosis of low-grade endometrial adenocarcinoma; vaginal versus other sites. Int J Gynecol Pathol. 2014;33:268–73.CrossRefPubMed
13.
Gaducci A, Cosio S, Fanucci A, Cristofani R, Genazzani AR. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer. Anticancer Res. 2000;20:1977–84.
14.
Salani R, Backes FJ, Fung Kee Fung M Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 2011;204:466–78.CrossRefPubMed
15.
Smith CJ, Heeren M, Nicklin JL, et al. Efficacy of routine follow-up in patients with recurrent uterine cancer. Gynecol Oncol. 2007;107:124–9.CrossRefPubMed
16.
Tjalma WAA, Van Dam PA, Makar AP, Cruickshank DJ. The clinical value and the coseffectiveness of follow-up in endometrial cancer patients. Int J Gynecol Cancer. 2004;14:931–7.CrossRefPubMed
17.
Aung L, Howells RE, Lim KC, Hudson E, Jones PW. Why routine clinical follow-up for patients with early stage endometrial cancer is not always necessary: a study on women in South Wales. Int J Gynecol Cancer. 2014;24:556–63.CrossRefPubMed
18.
Zakhour M, Li AJ, Walsh CS, Cass I, Karlan BY, Rimel BJ. Post treatment surveillance of type II endometrial cancer patients. Gynecol Oncol. 2013;131(3):609–12.CrossRefPubMed
19.
Carrara L, Gadducci A, Landoni F, et al. Could different follow-up modalities play a role in the diagnosis of asymptomatic endometrial cancer relapses?: an Italian multicentric retrospective analysis. Int J Gynecol Cancer. 2012;22(6):1013–9.CrossRefPubMed
20.
Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(6):33–8.
21.
Agboola OO, Grunfeld E, Coyle D, Perry GA. Costs and benefits of routine follow-up after curative treatment for endometrial cancer. Can Med Assoc. 1997;157:879–86.
22.
Bristow RE, Purinton SC, Santillan A, Diaz-Montes TP, Gardner GJ, Giuntoli RL 2nd. Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance. Gynecol Oncol. 2006;103:709–13.CrossRefPubMed
23.
Kew FM, Roberts AP, Cruickshank DJ. The role of routine follow-up after gynecological malignancy. Int J Gynecol Cancer. 2005;15:413–9.CrossRefPubMed
24.
Connor JP, Andrews JI, Anderson B, Buller RE. Computed tomography in endometrial carcinoma. Obstet Gynecol. 2000;95:692–6.CrossRefPubMed
25.
Kadkhodayan S, Shahriari S, Treglia G, Yousefi Z, Sadeghi R. Accuracy of 18-F-FDG PET imaging in the follow-up of endometrial cancer patients: systematic review and meta-analysis of the literature. Gynecol Oncol. 2013;128(2):397–404.CrossRefPubMed
26.
Ozcan Kara P, Kara T, Kaya Bm Kara Gedik G, Sari O. The value of FDG-PET/CT in the post-treatment evaluation of endometrial carcinoma: a comparison of PET/CT findings with conventional imaging and CA 125 as a tumour marker. Rev Esp Med Nucl Imagen Mol. 2012;31(5):257–60.PubMed
27.
Kitajima K, Suzuki K, Nakamoto Y, et al. Low-dose non-enhanced CT versus full-dose contrast-enhanced CT in integrated PET/CT studies for the diagnosis of uterine cancer recurrence. Eur J Radiol. 2012;81:3557–62.CrossRefPubMed
28.
Testa AC, Legge A D, Virgilio B, et al. Which imaging technique should we use in the follow-up of gynaecological cancer? Best Pract Res Clin Obstet Gynaecol 2014;28:769–91CrossRefPubMed
29.
Rose PG, Sommers RM, Reale FR, Hunter RE, Fournier L, Nelson BE. Serial serum Ca 125 measurements for evaluation of recurrence in patients with endometrial carcinoma. Obstet Gynecol. 1994;84:12–6.PubMed
30.
Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani AR. Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother. 2004;58(1):24–38.CrossRefPubMed